,i #aagth ,,congress #b;d ,session ,h4 ,r4 #gdgc ,,in ,,the ,,house ,,of ,,representatives ,april #g1 #bjbb,mrs4 ,carolyn ,b4 ,maloney of ,new ,york 7for herself1 ,mr4 ,cicilline1 ,mr4 ,nadler1 ,mr4 ,welch1 ,ms4 ,schakowsky1 ,ms4 ,porter1 ,mr4 ,de,saulnier1 and ,mr4 ,raskin7 introduced the following bill2 which was referred to the ,committee on the ,judiciary ,a ,,bill ,to prohibit pharmaceutical manufacturers from interfering with therapeutically equivalent or interchangeable substitution decisions by health care providers to limit competition from a generic drug or biosimilar biological product1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,generic ,substitution ,noninterference ,act4 #b4 ,declaration of purposes ,the purposes of this ,act are-- 7#a7 to enhance competition in the pharmaceutical market by stopping anticompetitive practices that limit or prevent competition from generic drugs and biosimilar biological products1 7#b7 to support the purposes and intent of antitrust law by prohibiting anticompetitive practices in the pharmaceutical industry that harm consumers1 and 7#c7 to preserve physician autonomy4 #c4 ,interference with provider substitution decisions 7a7 ,prohibition ,it shall be unlawful for a pharmaceutical manufacturer-- 7#a7 to provide any item or service1 or anything of value1 for the purpose of aiding or assisting a health care provider to request or direct that a drug be dispensed as written or brand name only when a generic drug or biosimilar biological product is available1 including any prescription notepad or prescription stamp1 but not including any product sample1 or 7#b7 to direct a health care provider to write dispense as written1 brand name only1 or another similar notation or direction on a prescription when a generic drug or biosimilar biological product is available4 7b7 ,limitation ,nothing in this section prevents a health care provider from exercising the provider's own medical judgment to prescribe any drug or biologic product4 7c7 ,civil penalty actions ,if the ,commission has reason to believe that a pharmaceutical manufacturer has violated or is violating this ,act1 the ,federal ,trade ,commission may commence a civil action to recover a civil penalty and seek other appropriate relief in a district court of the ,united ,states against the pharmaceutical manufacturer4 ,except as otherwise provided in section #af7;a77#b7 of the ,federal ,trade ,commission ,act 7#ae ,u4,s4,c4 #ef7;a77#c771 the ,commission shall have exclusive authority to commence or defend1 and supervise the litigation of1 any civil action under paragraph 7#a7 and any appeal of such action in its own name by any of its attorneys designated by it for such purpose1 unless the ,commission authorizes the ,attorney ,general to do so4 ,the ,commission shall inform the ,attorney ,general of the exercise of such authority and such exercise shall not preclude the ,attorney ,general from intervening on behalf of the ,united ,states in such action and any appeal of such action as may be otherwise provided by law4 ,the civil penalty shall be sufficient to deter violations of this section1 but in no event shall be greater than three times the gross revenues received for sales of the brand-name drug during the period in which the prohibited conduct occurred4 ,in determining the amount of the civil penalty1 the court shall take into account-- 7#a7 the nature1 circumstances1 extent1 and gravity of the violation with respect to the pharmaceutical manufacturer1 7#b7 the degree of culpability1 7#c7 the history of violations1 7#d7 the ability to pay1 and any effect on the ability to continue doing business1 and 7#e7 other matters that justice requires4 7d7 ,unfair method of competition ,a violation of this ,act shall also constitute an unfair method of competition under section #e7;a77#a7 of the ,federal ,trade ,commission ,act 7#ae ,u4,s4,c4 #de7;a77#a774 7e7 ,enforcement authority ,except as otherwise provided in subsection 7c71 the ,commission shall enforce this ,act in the same manner1 by the same means1 and with the same jurisdiction1 powers1 and duties as though all applicable terms and provisions of the ,federal ,trade ,commission ,act 7#ae ,u4,s4,c4 #da et seq47 were incorporated into and made a part of this ,act4 7f7 ,actions by states 7#a7 ,in general ,in any case in which the attorney general of a ,state has reason to believe that an interest of the residents of that ,state has been or is threatened or adversely affected by the engagement of a pharmaceutical manufacturer in any conduct described in subsection 7a71 the ,state1 as parens patriae1 may bring a civil action on behalf of the residents of the ,state in a district court of the ,united ,states of appropriate jurisdiction to enjoin that practice1 to obtain damages1 restitution1 or other compensation on behalf of residents of such ,state1 or to obtain such further and other relief as the court may deem appropriate4 7#b7 ,notice ,the ,state shall serve prior written notice of any civil action under this subsection upon the ,commission and provide the ,commission with a copy of its complaint1 except that if it is not feasible for the ,state to provide such prior notice1 the ,state shall serve such notice immediately upon instituting such action4 ,upon receiving a notice respecting a civil action1 the ,commission shall have the right to-- 7,a7 intervene in such action1 7,b7 upon so intervening1 to be heard on all matters arising therein1 and 7,c7 to file petitions for appeal4 7#c7 ,construction ,for purposes of bringing a civil action under this subsection1 nothing in this ,act shall prevent an attorney general from exercising the powers conferred on the attorney general by the laws of such ,state to conduct investigations1 or to administer oaths or affirmations1 or to compel the attendance of witnesses or the production of documentary and other evidence4 7#d7 ,actions by commission ,whenever a civil action has been instituted by or on behalf of the ,commission for violation of this ,act1 no ,state may1 during the pendency of such action instituted by or on behalf of the ,commission1 institute a civil action under this subsection against any defendant named in the complaint in such action for violation of this ,act4 7#e7 ,venue2 service of process ,any civil action brought under this subsection in a district court of the ,united ,states may be brought in the district in which the defendant is found1 is an inhabitant1 or transacts business or wherever venue is proper under section #acia of title #bh4 ,process in such an action may be served in any district in which the defendant is an inhabitant or in which the defendant may be found4 7g7 ,definitions ,in this section3 7#a7 ,antitrust laws ,the term antitrust laws has the meaning given the term in subsection 7a7 of the #ast section of the ,clayton ,act 7#ae ,u4,s4,c4 #ab7;a774 7#b7 ,biosimilar biological product ,the term biosimilar biological product means a biological product licensed under section #cea7k7 of the ,public ,health ,service ,act4 7#c7 ,brand name drug ,the term brand name drug means a drug approved or licensed under section #eje7;c7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act or section #cea7;a7 of the ,public ,health ,service ,act4 7#d7 ,generic drug ,the term generic drug means a drug approved under section #eje7;j7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act4 7#e7 ,health care provider ,the term health care provider means any individual or entity1 including any pharmacy1 that participates in any ,federal health care program 7as defined in section #aabh;,b7f77 of the ,social ,security ,act4 7#f7 ,pharmaceutical manufacturer ,the term pharmaceutical manufacturer means the holder of-- 7,a7 an application approved under section #eje7;c7 or #eje7;j7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 or 7,b7 a license under section #cea7;a7 or #cea7k7 of the ,public ,health ,service ,act4 7h7 ,rule of construction ,except to the extent this ,act establishes an additional basis for liability enforced as provided herein1 nothing in this ,act shall modify1 impair1 limit1 or supersede the applicability of the antitrust laws1 as defined in subsection 7a7 of the #ast section of the ,clayton ,act 7#ae ,u4,s4,c4 #ab7;a771 and of section #e7;a7 of the ,federal ,trade ,commission ,act 7#ae ,u4,s4,c4 #de7;a774 ,nothing in this ,act shall be construed to limit the authority of the ,federal ,trade ,commission under any other provision of law4 7i7 ,severability ,if any provision of this ,act1 or the application of such provision1 to any person or circumstance is held to be unconstitutional1 the remainder of this ,act1 and the application of the remaining provisions of this ,act1 to any person or circumstance shall not be affected4